 The duration of effectiveness of SARS-CoV-2 vaccination is not yet known. Here, the authors present preliminary evidence of BNT-162B2 vaccine waning across all age groups above 16, with a higher incidence of infection in people who received their second dose early in 2021 compared to later in the year. This article was authored by Barrick Ms. Rohe, Ronny Lowton, Nick Orkstein, and others.